The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients
- PMID: 2474312
- PMCID: PMC1379684
- DOI: 10.1111/j.1365-2125.1989.tb03466.x
The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients
Abstract
1. Vigabatrin, 50 mg kg-1, was administered orally as add-on therapy to 11 patients with drug-resistant complex partial epilepsy as a single dose, then once every third day for 2 months, every other day for 2 months and daily for 1 month. 2. Lumbar punctures were carried out prior to treatment and at the end of each dosage regimen and cerebrospinal fluid (CSF) evaluated for concentrations of free and total GABA, homocarnosine (GABA-histidine dipeptide), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA) and vigabatrin. 3. Each regimen resulted in significant increases in CSF concentrations of free and total GABA and homocarnosine compared with the immediately preceding regimen. 4. CSF concentrations of HVA significantly increased after a single vigabatrin dose but returned to pre-treatment levels with subsequent dosing schedules. In contrast, 5-HIAA concentrations also increased with the single dose but were significantly decreased, compared with pre-treatment values, following alternate day and daily vigabatrin administration. 5. Seizure frequency progressively decreased with decreasing dosing interval. Daily vigabatrin administration was associated with greater than 50% decrease in seizures in 8 of the 10 patients treated.
Similar articles
-
Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy.Epilepsy Res. 1988 Mar-Apr;2(2):96-101. doi: 10.1016/0920-1211(88)90025-3. Epilepsy Res. 1988. PMID: 3143561
-
Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid.J Child Neurol. 1991;Suppl 2:S11-6. J Child Neurol. 1991. PMID: 1719063
-
Levels of total gamma-aminobutyric acid (GABA), free GABA and homocarnosine in cerebrospinal fluid of epileptic patients before and during gamma-vinyl-GABA (vigabatrin) treatment.J Neurol Sci. 1988 Dec;88(1-3):83-93. doi: 10.1016/0022-510x(88)90207-9. J Neurol Sci. 1988. PMID: 3225631
-
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.Drugs. 1991 Jun;41(6):889-926. doi: 10.2165/00003495-199141060-00007. Drugs. 1991. PMID: 1715266 Review.
-
Vigabatrin.Ann Pharmacother. 1993 Feb;27(2):197-204. doi: 10.1177/106002809302700215. Ann Pharmacother. 1993. PMID: 8439699 Review.
Cited by
-
Visual electrophysiological effect of a GABA transaminase blocker.Doc Ophthalmol. 1998-1999;97(2):179-88. doi: 10.1023/a:1002045223358. Doc Ophthalmol. 1998. PMID: 10765970 Clinical Trial.
-
Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. The Italian Study Group on Vigabatrin.Ital J Neurol Sci. 1992 Dec;13(9):741-7. doi: 10.1007/BF02229159. Ital J Neurol Sci. 1992. PMID: 1483856 Clinical Trial.
-
Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.Clin Pharmacokinet. 1996 Jun;30(6):403-15. doi: 10.2165/00003088-199630060-00001. Clin Pharmacokinet. 1996. PMID: 8792055 Review.
-
Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.Mol Neurobiol. 1998 Feb;16(1):97-121. doi: 10.1007/BF02740605. Mol Neurobiol. 1998. PMID: 9554704 Review.
-
Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting.Br J Clin Pharmacol. 2014 Nov;78(5):981-95. doi: 10.1111/bcp.12414. Br J Clin Pharmacol. 2014. PMID: 24802902 Free PMC article. Clinical Trial.